Safety and Immunogenicity of the Malaria Vaccine Candidate GMZ2 in African Children
Author Information
Author(s): Bélard Sabine, Issifou Saadou, Hounkpatin Aurore B., Schaumburg Frieder, Ngoa Ulysse Ateba, Esen Meral, Fendel Rolf, de Salazar Pablo Martinez, Mürbeth Raymund E., Milligan Paul, Imbault Nathalie, Imoukhuede Egeruan Babatunde, Theisen Michael, Jepsen Søren, Noor Ramadhani A., Okech Brenda, Kremsner Peter G., Mordmüller Benjamin
Primary Institution: Medical Research Unit, Albert Schweitzer Hospital, Lambaréné, Gabon
Hypothesis
The study aims to evaluate the safety and immunogenicity of the GMZ2 malaria vaccine in children aged 1 to 5 years in Gabon.
Conclusion
Both 30 µg and 100 µg doses of the GMZ2 vaccine are safe and induce a strong immune response in young Gabonese children.
Supporting Evidence
- GMZ2 was well tolerated and induced antibodies and memory B-cells against malaria.
- Antibody concentrations increased significantly after vaccination compared to controls.
- Both vaccine doses were associated with mild adverse events, which resolved without treatment.
Takeaway
The GMZ2 malaria vaccine is safe and helps kids build immunity against malaria.
Methodology
Thirty children aged 1 to 5 were randomized to receive either GMZ2 or a control rabies vaccine, with follow-ups for one year.
Potential Biases
Potential bias in participant selection and reporting of adverse events.
Limitations
The small sample size limits the generalizability of the findings.
Participant Demographics
Children aged 1 to 5 years from Lambaréné, Gabon.
Statistical Information
P-Value
p<0.05
Confidence Interval
95%CI: 11,34
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website